Full Preloaded Aspheric Hydrophobic Intraocular Lens

Full Preloaded Aspheric Hydrophobic Intraocular Lens​

MOM Smart Innovation Platform
MOM Smart Innovation Platform is a self-developed intraocular lens technology platform by Simedice. It integrates Simedice's unique advantages in materials, optical design, and manufacturing processes, ensuring that each lens maintains consistent high quality. The platform strives to bring patients more durable and sharper visual quality.

Material:

• Higher Refractive Index: 1.55
• Precisely filter harmful violet light
• Unique low glass transition temperature: 7°C ​The lower the Tg(Glass Transition Temperature) of the material, the more foldable the IOL. The Tg of Simedice IOL is 7°C. So the IOL can be folded and inserted through very Small Incisions under Lower Injection Forces.
  

Optic&design:

• Modified C Loop, excellent Rotation Stability
• High-order even aspheric design to prevent decentration

Molding:

• Ultra-precision Cast Molding, more accurate Lens Power
• Low PCO rate

ADVANTAGES

1. Simedice IOL design has two features to reduce the probability and intensity of stray light reflection from the lOL edge and avoid the scattered light from the lOL edge reflectionwhen the pupil becomes large at night.
2. Excellent material compliance highly fits posterior capsule.
3. Excellent memory-superior foldability, moderate and gentle release.

STABILITY & LOW RATE OF POSTERIOR CAPSULE OPACIFICATION (PCO)

1. Hydrophobic acrylate material of Simedice IOLs has great biocompatibility and excellent posterior capsule adhesion, resulting in less cell migration for significant reduction of PCO rate post-implantation.
2. Sharp Square Edge effectively prevents PCO.

Fully Preloaded Injection System

1. Intuitive, easy handling replaces manual loading
2. Less risk of IOL damage, cross-contamination and mishandling
3. Faster IOL delivery procedures improves efficiency and productivity.

 
Haohai Vision is the core ophthalmic business segment of

Shanghai Haohai Biological Technology Co., Ltd.

— the first biomedical company listed on both STAR Market (688366) and Hong Kong Stock Exchange (06826).

We are committed to providing comprehensive eye health solutions for global patients across the full eye care lifecycle, shaping a new future for the ophthalmic industry.

With 18 years of focus since 2007, we have built a complete industrial chain covering raw materials, R&D, manufacturing and distribution.

Today, Haohai Vision is:

• One of the world’s largest IOL manufacturers
• A leading player in China’s IOL market with annual output over 1 million units
• No.1 in China ophthalmic visco device (OVD) market for 18 consecutive years
• Products exported to more than 30 countries